Who makes Swallowed ticagrelor?

Swallowed ticagrelor is developed by Centro Hospitalario La Concepcion.

What development phase is Swallowed ticagrelor in?

Swallowed ticagrelor is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Swallowed ticagrelor

Centro Hospitalario La Concepcion · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Swallowed ticagrelor
Sponsor	Centro Hospitalario La Concepcion
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Ticagrelor Administered as Standard Tablet or Orodispersible Formulation (PHASE3)
Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome (PHASE4)
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI (PHASE4)
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Swallowed ticagrelor CI brief — competitive landscape report
Swallowed ticagrelor updates RSS · CI watch RSS
Centro Hospitalario La Concepcion portfolio CI